Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XKH004 in Moderate-to-Severe Active Ankylosing Spondylitis
NCT07498634Phase 3Completed
- Sponsor
- Kanova
- Start
- Sep 2023
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ankylosing spondylitis (AS) comparing XKH004 with Placebo -> XKH004 (2 arms). Primary endpoint: Assessment of SpondyloArthritis international Society 40% response at 16 weeks. Started Sep 2023; status: completed.
02
Drugs
lzm012
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT07498634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07498634.